当前位置: X-MOL 学术Pediatr. Obes. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.
Pediatric Obesity ( IF 3.8 ) Pub Date : 2020-02-16 , DOI: 10.1111/ijpo.12624
D Weghuber 1, 2 , A Forslund 3, 4 , H Ahlström 5, 6 , A Alderborn 7 , K Bergström 8 , S Brunner 1 , J Cadamuro 9 , I Ciba 3, 4 , M Dahlbom 3, 4 , V Heu 1 , J Hofmann 1 , H Kristinsson 7 , J Kullberg 5, 6 , A Ladinger 10 , F B Lagler 11 , M Lidström 4 , H Manell 3, 7 , M Meirik 4 , K Mörwald 2 , K Roomp 12 , R Schneider 12 , H Vilén 4 , K Widhalm 2, 13 , F Zsoldos 2 , P Bergsten 3, 4, 7
Affiliation  

Pharmacological treatment options for adolescents with obesity are very limited. Glucagon‐like‐peptide‐1 (GLP‐1) receptor agonist could be a treatment option for adolescent obesity.

中文翻译:

肥胖青少年每周艾塞那肽每周6个月的随机,双盲,安慰剂对照试验。

肥胖青少年的药物治疗选择非常有限。胰高血糖素样肽-1(GLP-1)受体激动剂可能是青少年肥胖的治疗选择。
更新日期:2020-02-16
down
wechat
bug